Dr. Kevin Chan, M.D

NPI: 1437330081
Total Payments
$156,493
2018 Payments
$143,301
Companies
3
Transactions
46

Payment Breakdown by Category

Consulting$128,483 (82.1%)
Travel$20,999 (13.4%)
Other$6,000 (3.8%)
Food & Beverage$560.64 (0.4%)
Education$450.73 (0.3%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $128,483 12 82.1%
Travel and Lodging $20,999 21 13.4%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,000 1 3.8%
Food and Beverage $560.64 11 0.4%
Education $450.73 1 0.3%

Top Paying Companies

Company Total Records Latest Year
Relypsa, Inc. $117,330 14 $0 (2018)
Merck Sharp & Dohme Corporation $20,644 28 $0 (2018)
Daiichi Sankyo Inc. $18,519 4 $0 (2018)

Payment History by Year

Year Amount Transactions Top Company
2018 $143,301 28 Relypsa, Inc. ($110,289)
2017 $13,191 18 Relypsa, Inc. ($7,041)

All Payment Transactions

46 individual payment records from CMS Open Payments — Page 1 of 2

Date Company Product Nature Form Amount Type
08/16/2018 Daiichi Sankyo Inc. Savaysa (Drug) Consulting Fee Cash or cash equivalent $8,470.00 General
Category: Thrombosis
07/30/2018 Relypsa, Inc. Veltassa (Drug) Consulting Fee Cash or cash equivalent $30,170.00 General
Category: Hyperkalemia
07/12/2018 Merck Sharp & Dohme Corporation Travel and Lodging In-kind items and services $202.25 General
07/12/2018 Merck Sharp & Dohme Corporation Food and Beverage In-kind items and services $68.96 General
06/04/2018 Merck Sharp & Dohme Corporation Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $6,000.00 General
06/04/2018 Merck Sharp & Dohme Corporation Travel and Lodging Cash or cash equivalent $195.16 General
06/04/2018 Merck Sharp & Dohme Corporation Travel and Lodging Cash or cash equivalent $150.00 General
05/25/2018 Relypsa, Inc. Veltassa (Drug) Consulting Fee Cash or cash equivalent $15,977.50 General
Category: Hyperkalemia
05/25/2018 Merck Sharp & Dohme Corporation ZEPATIER (Drug) Education In-kind items and services $450.73 General
Category: INFECTIOUS DISEASE
05/25/2018 Merck Sharp & Dohme Corporation ZEPATIER (Drug) Travel and Lodging In-kind items and services $315.51 General
Category: INFECTIOUS DISEASE
05/25/2018 Merck Sharp & Dohme Corporation ZEPATIER (Drug) Travel and Lodging In-kind items and services $268.00 General
Category: INFECTIOUS DISEASE
05/25/2018 Merck Sharp & Dohme Corporation ZEPATIER (Drug) Food and Beverage In-kind items and services $95.66 General
Category: INFECTIOUS DISEASE
05/24/2018 Merck Sharp & Dohme Corporation ZEPATIER (Drug) Travel and Lodging In-kind items and services $6,132.51 General
Category: INFECTIOUS DISEASE
05/24/2018 Merck Sharp & Dohme Corporation ZEPATIER (Drug) Travel and Lodging In-kind items and services $268.00 General
Category: INFECTIOUS DISEASE
05/24/2018 Merck Sharp & Dohme Corporation ZEPATIER (Drug) Travel and Lodging In-kind items and services $67.81 General
Category: INFECTIOUS DISEASE
05/24/2018 Merck Sharp & Dohme Corporation ZEPATIER (Drug) Food and Beverage In-kind items and services $10.30 General
Category: INFECTIOUS DISEASE
05/23/2018 Merck Sharp & Dohme Corporation ZEPATIER (Drug) Travel and Lodging In-kind items and services $268.00 General
Category: INFECTIOUS DISEASE
05/07/2018 Daiichi Sankyo Inc. Savaysa (Drug) Travel and Lodging In-kind items and services $9,593.41 General
Category: Thrombosis
05/07/2018 Daiichi Sankyo Inc. Savaysa (Drug) Travel and Lodging In-kind items and services $274.80 General
Category: Thrombosis
05/06/2018 Daiichi Sankyo Inc. Savaysa (Drug) Travel and Lodging In-kind items and services $181.25 General
Category: Thrombosis
04/06/2018 Relypsa, Inc. Veltassa (Drug) Consulting Fee Cash or cash equivalent $20,947.50 General
Category: Hyperkalemia
04/01/2018 Relypsa, Inc. Veltassa (Drug) Consulting Fee Cash or cash equivalent $103.59 General
Category: Hyperkalemia
03/05/2018 Relypsa, Inc. Veltassa (Drug) Consulting Fee Cash or cash equivalent $19,845.00 General
Category: Hyperkalemia
03/05/2018 Relypsa, Inc. Veltassa (Drug) Consulting Fee Cash or cash equivalent $7,228.00 General
Category: Hyperkalemia
01/22/2018 Relypsa, Inc. Veltassa (Drug) Consulting Fee Cash or cash equivalent $15,085.00 General
Category: Hyperkalemia

About Dr. Kevin Chan, M.D

Dr. Kevin Chan, M.D is a Nephrology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/23/2007. The National Provider Identifier (NPI) number assigned to this provider is 1437330081.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kevin Chan, M.D has received a total of $156,493 in payments from pharmaceutical and medical device companies, with $143,301 received in 2018. These payments were reported across 46 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($128,483).

Practice Information

  • Specialty Nephrology
  • Location Boston, MA
  • Active Since 11/23/2007
  • Last Updated 11/10/2011
  • Taxonomy Code 207RN0300X
  • Entity Type Individual
  • NPI Number 1437330081

Products in Payments

  • Veltassa (Drug) $117,330
  • Savaysa (Drug) $18,519
  • ZEPATIER (Drug) $7,877

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Nephrology Doctors in Boston